{"id":"diaziquone","rwe":[{"pmid":"22937180","year":"2012","title":"Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer.","finding":"","journal":"Translational oncology","studyType":"Clinical Study"},{"pmid":"20192247","year":"2010","title":"Cytotoxic activities of several geranyl-substituted flavanones.","finding":"","journal":"Journal of natural products","studyType":"Clinical Study"},{"pmid":"16213738","year":"2006","title":"The lethal effect of bis-type azridinylnaphthoquinone derivative on oral cancer cells (OEC-M1) associated with anti-apoptotic protein bcl-2.","finding":"","journal":"Bioorganic & medicinal chemistry","studyType":"Clinical Study"},{"pmid":"15634030","year":"2005","title":"Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.","finding":"","journal":"Clinical pharmacokinetics","studyType":"Clinical Study"},{"pmid":"15572587","year":"2005","title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.","finding":"","journal":"Blood","studyType":"Clinical Study"}],"tags":[{"label":"diaziquone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Cross-Linking Reagents","category":"pharmacology"},{"label":"Indicators and Reagents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aziridinylbenzoquinone","offLabel":[],"synonyms":["diaziquone","aziridinylbenzoquinone"],"timeline":[],"approvals":[],"brandName":"Aziridinylbenzoquinone","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"diaziquone","explanation":"Imagine your DNA as a long, twisted ladder. Diaziquone is like a chemical that goes into the ladder and causes it to break, making it impossible for the cell to function. This ultimately leads to the death of the cell, which can be beneficial in treating cancer.","oneSentence":"Diaziquone works by inducing DNA cross-links and strand breaks, leading to cell death.","technicalDetail":"Diaziquone exerts its cytotoxic effects through the formation of DNA cross-links and strand breaks, primarily via the alkylation of DNA at the N7 position of guanine, leading to DNA damage and subsequent cell death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/853","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIAZIQUONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:33:02.635505","biosimilars":[],"competitors":[],"genericName":"diaziquone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"FQL5EUP13W","CHEBI":"CHEBI:90185","INN_ID":"5124","UMLSCUI":"C0113600","ChEMBL_ID":"CHEMBL36016","KEGG_DRUG":"D03774","DRUGBANK_ID":"DB17174","PUBCHEM_CID":"42616","MESH_SUPPLEMENTAL_RECORD_UI":"C029108"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":154,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2012 Aug","pmid":"22937180","title":"Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer.","journal":"Translational oncology"},{"date":"2010 Apr 23","pmid":"20192247","title":"Cytotoxic activities of several geranyl-substituted flavanones.","journal":"Journal of natural products"},{"date":"2006 Jan 1","pmid":"16213738","title":"The lethal effect of bis-type azridinylnaphthoquinone derivative on oral cancer cells (OEC-M1) associated with anti-apoptotic protein bcl-2.","journal":"Bioorganic & medicinal chemistry"},{"date":"2005","pmid":"15634030","title":"Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.","journal":"Clinical pharmacokinetics"},{"date":"2005 May 1","pmid":"15572587","title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.","journal":"Blood"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aziridinylbenzoquinone (Diaziquone) is a small molecule diaziquone with unknown target and mechanism of action. It is not FDA-approved for any indications. The commercial status of Diaziquone is unclear, and it is not known whether it is patented or available as a generic. Diaziquone is a chemotherapeutic agent that has been investigated for its potential to treat various types of cancer, but its development has been limited due to its toxicity profile. Further research is needed to fully understand the potential benefits and risks of this compound.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}